Search Results for: CLINICAL RESEARCH Behind the Wave
Articles
CLINICAL RESEARCH - Behind the Wave: Clinical Research in a Digital Transformation Era May 1, 2017
Kai Langel believes the remote research model and purpose-built technology offer the tools and the right process to help modernize clinical research and bring it closer to the high standard set by today’s consumer technologies.
CLINICAL TRIALS - The Power of AI in Overcoming Patient Diversity Challenges January 26, 2024
Isaac Bentwich, PhD, explores why patient diversity is such a challenge for clinical trials, where that pain is often felt the most, some of the regulatory, technological, and industry changes already underway to solve the clinical trial gap, and where AI changes the future of patient diversity.
DRUG DEVELOPMENT EXECUTIVE - Poseida Therapeutics: Creating the Next Wave of Cell & Gene Therapies With the Capacity to Cure August 26, 2021
Eric M. Ostertag, MD, PhD, CEO of Poseida Therapeutics, discusses the company’s innovative approach to develop safer, more effective, accessible and affordable cell and gene therapies for patients.
EXECUTIVE INTERVIEW - Poseida Therapeutics: Creating the Next Wave of Cell & Gene Therapies With the Capacity to Cure June 1, 2021
Eric M. Ostertag, MD, PhD, Chief Executive Officer of Poseida Therapeutics, discusses the company’s innovative approach to develop safer, more effective, accessible and affordable cell and gene therapies for patients.
Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy May 13, 2019
Theralase Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (PDCs)...Teva & Abingworth Enter Strategic Development Funding Agreement April 1, 2024
Collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler (TEV-‘248) program….
DRUG DEVELOPMENT - Bringing New Drugs to Patients Faster by Integrating Traditionally Separate Pharma Development Functions August 31, 2020
Nutan Gangrade, PhD, says reducing R&D project timelines saves on overhead in development while increasing the likelihood of primacy in the marketplace (which engenders significantly more sales) and describes new approaches drug developers are taking to streamline drug development.
Horizon Discovery & Pharmahungary Report Positive Early Stage Results for Novel Micro-RNA Therapeutic April 1, 2020
Horizon Discovery Group plc and Pharmahungary Group recently announced positive early stage results for a novel micro-RNA therapeutic for…………..
BioXcel Therapeutics Announces FDA Clearance of IND Application June 6, 2019
BioXcel Therapeutics recently announced an update of its immuno-oncology program for BXCL701, an orally available systemic innate-immune activator with dual...ADVANCED DELIVERY DEVICES - How Data Hubs & Smart Devices Are Enabling the Rise of Therapeutic Ecosystems January 8, 2016
Stephen Allan discusses how unique collaborations between tech and biotech reflect a new paradigm in how therapeutics are being commercialized and marketed under the new pay-for-performance healthcare model.
MANAGEMENT INSIGHT - Forging a Blue Ocean Strategy to Work in a Red Pharma Ocean January 7, 2016
I used to hate the circus. Crowds, sticky cotton candy fingers, poodles utterly failing to take the place of lions...MANAGEMENT INSIGHT - The Biotech Bubble: What Goes Up Must Come Down May 6, 2014
Physicists know it. Coffee drinkers live it. Roller coasters capitalize on it. Yet stock market investors - even coffee-drinking physicist-investors...BIOAVAILABILITY ENHANCEMENT - Navigating a Broad Spectrum of Solubilization Technologies: Part III of III November 19, 2013
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., concludes his multiple-part series discussing today’s most challenging issues in solubility.
ADVANCED DELIVERY DEVICES - The Reconstitution Revolution October 15, 2013
Alan Shortall believes with dual-chamber syringes and other emerging device technologies now addressing key market requirements for intuitive reconstitution and injection, the pharmaceutical market for therapies suitable for reconstitution and mixing at the point of delivery is poised for significant rates of growth.
